At C4 Therapeutics we are developing novel drugs based on the DEGRONIMID™ paradigm. These drugs are a new class of small molecules that direct the machinery of the ubiquitin-proteasome system to selectively degrade disease-relevant proteins for therapeutic benefit. This paradigm shift in drug development will potentially provide new opportunities to target traditionally difficult diseases and resistance mechanisms.
C4 Therapeutics Announces World-Class Scientific Advisory Board
Cambridge, MA. – November 17, 2016 – C4 Therapeutics (C4T) today announced Ken Anderson, M.D., Nathanael Gray, Ph. D., Christopher Kirk, Ph. D. and Eric Fischer, Ph. D as the members of its Scientific Advisory Board (SAB).
“We are thrilled to have Ken, Nathanael, Chris, and Eric play an important role as our advisors at C4T,” said Andrew Phillips, Ph.D., President and Chief Scientific Officer of C4 Therapeutics. “Their world-renowned expertise in clinical oncology, drug discovery and development, and the basic-science of the ubiquitin-proteasome system will be invaluable as we both advance drug candidates toward the clinic and develop new tools and technologies that keep C4T at the cutting edge.” read more...
C4 Therapeutics Appoints Andrea Armstrong as CAO
Cambridge, MA. – September 22, 2016 – C4 Therapeutics (C4T) today announced that Andrea Armstrong has been promoted to Chief Administrative Officer. She joined C4T as a human resources consultant in January, 2016 and transitioned to full-time as the Senior Vice President of Human Resources in June, 2016. Ms. Armstrong has led the human resources function with a focus on talent acquisition efforts and will now also assume responsibility for facilities and laboratory operations, environmental health and safety, IT and office management, and internal communications.
“Andrea has been integral to the growth of C4T to this point,” said Andrew Phillips, Ph.D., President and Chief Scientific Officer of C4 Therapeutics. “In addition to Andrea’s talents in human resources, her extensive organizational development and operational experience will bring much to our next phase of growth. I look forward to working with her in this expanded role.” read more...
Names C4 Therapeutics as one of its “Fierce 15” Biotech Companies of 2016
Cambridge, MA. – September 19, 2016 – C4 Therapeutics (C4T) today announced that it has been named by FierceBiotech as one of 2016’s Fierce 15 biotechnology companies, designating it as one of the most promising private biotechnology companies in the industry.
“We are humbled to be named a 2016 Fierce 15 company,” said Andrew Phillips, Ph.D., President and Chief Scientific Officer of C4 Therapeutics. “Since launching the company in January this year, the C4T team has rapidly built a world class science organization, made tremendous headway on internal projects, and moved forward with our partner Roche. The Fierce15 award is a testament to this momentum, and also to the potential of our approach to targeted protein degradation for developing transformative new therapeutics.” read more...
What We Do